drugset / Trial / NCT07253259
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
Phase 0
Recruiting
36 enrolled
Grit Biotechnology
Institute of Hematology & Blood Diseases Hospital, China · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).
Timeline
- Start
- 2025-12-18
- Primary completion
- 2027-11-30
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GT729 | Unknown | — | — |